Levetiracetam Tablet, Film Coated
Product Images NDC 68788-7884

9 FDA label images from Preferred Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-7884). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetamtabletsstructure (Levetiracetamtabletsstructure)

Levetiracetamtabletsstructure (Levetiracetamtabletsstructure)
Chemical structure of the active ingredient Levetiracetam. The diagram shows the molecular arrangement including a pyrrolidone ring attached to an ethyl group and an amide side chain.*
FDA Label Image

Levetiracetamtabletsfigure1 (Levetiracetamtabletsfigure1)

Levetiracetamtabletsfigure1 (Levetiracetamtabletsfigure1)
A bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, showing lower values for placebo and higher values for Levetiracetam doses. The chart includes sample sizes for each group below the bars.*
FDA Label Image

Levetiracetamtabletsfigure2 (Levetiracetamtabletsfigure2)

Levetiracetamtabletsfigure2 (Levetiracetamtabletsfigure2)
Bar chart showing the percentage of patients in a study receiving placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients from 0% to 45%. The placebo group shows 6.3%, Levetiracetam 1000 mg/day shows 20.8%, and Levetiracetam 2000 mg/day shows 35.2% of patients in each respective category.*
FDA Label Image

Levetiracetamtabletsfigure3 (Levetiracetamtabletsfigure3)

Levetiracetamtabletsfigure3 (Levetiracetamtabletsfigure3)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The percentage of patients is shown on the vertical axis, with Placebo at 14.4% and Levetiracetam 3000 mg/day at 39.4%. This chart illustrates patient response rates for a Levetiracetam treatment vs. placebo.*
FDA Label Image

Levetiracetamtabletsfigure4 (Levetiracetamtabletsfigure4)

Levetiracetamtabletsfigure4 (Levetiracetamtabletsfigure4)
A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The vertical axis represents the percentage of patients from 0% to 45%. The placebo group (N=97) shows 19.6%, while the Levetiracetam group (N=101) shows 44.6% with an asterisk above the bar indicating statistical significance.*
FDA Label Image

Levetiracetamtabletsfigure5 (Levetiracetamtabletsfigure5)

Levetiracetamtabletsfigure5 (Levetiracetamtabletsfigure5)
A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The graph shows approximately 19.6% of patients in the placebo group and 43.1% in the Levetiracetam group, with patient counts noted as 51 for placebo and 58 for Levetiracetam.*
FDA Label Image

Levetiracetamtabletsfigure6 (Levetiracetamtabletsfigure6)

Levetiracetamtabletsfigure6 (Levetiracetamtabletsfigure6)
A bar chart comparing the percentage of patients in two groups: Placebo (N=84) and Levetiracetam (N=79). The chart shows 45.2% for the Placebo group and 72.2% for the Levetiracetam group on the y-axis labeled '% of Patients.'*
FDA Label Image
FDA Label Image

Levetiracetam Tablets 250mg (Leveannora250mg30scount)

Levetiracetam Tablets 250mg (Leveannora250mg30scount)
Levetiracetam Tablets 250 mg film-coated oral tablets label. The label includes dosage strength, generic name, and manufacturer details (Camber Pharmaceuticals, Inc.). It has directions for use in English and Spanish, storage instructions, and a caution about federal law prohibiting drug transfer. The label design features yellow blocks with black text and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.